BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Now, Ferring Pharmaceuticals Challenges FDA Over Market Exclusivity


1/31/2013 7:35:43 AM

Call it a coincidence, but for the second time this month, a drugmaker is taking the rare step of challenging the FDA over its decisionmaking for marketing exclusivity. Specifically, Ferring Pharmaceuticals has filed a citizen’s petition asking the agency to change its approach for granting exclusivity to combination medications. At stake is the opportunity to wring more revenue out of its Prepopik solution for colonoscopy preparation, which was approved last July. The petition was filed shortly after Gilead Sciences filed a very similar petition concerning exclusivity for its Stribild AIDS treatment, a fixed-dose combination drug that was also approved last summer. Ferring argues that five years of exclusivity is warranted because Prepopik contains an active ingredient, sodium picosulfate, that has never before been a component of an approved new drug application, unlike two other ingredients. But the FDA has regularly interpreted the law to say that drugmakers do not receive five years of exclusivity unless all ingredients are new. In its own petition, Gilead (GILD) made a similar argument because two of four active ingredients in Stribild are new. But as we noted recently, the FDA currently awards only three years of exclusivity if a combination treatment contains a previously approved ingredient, and if a drugmaker conducted new clinical studies that were essential to approval. The arguments have potentially significant implications if more drugmakers first seek approval for combination medications with one or more new active ingredients. Most of the time, though, drugmakers try to win approval of a new single-ingredient drug in order to secure five years of exclusivity and then seek FDA approval of a fixed-dose combination including that drug.

Read at Pharmalot


Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->